Search Results - "Giacomini, Paul S"

Maraviroc and JC Virus–Associated Immune Reconstitution Inflammatory Syndrome by Giacomini, Paul S, Rozenberg, Ayal, Metz, Imke, Araujo, David, Arbour, Nathalie, Bar-Or, Amit

“…The immune reconstitution inflammatory syndrome can be a serious complication of immune reversal in the treatment of progressive multifocal…”
Get full text

Managing Multiple Sclerosis: Treatment Initiation, Modification, and Sequencing by Freedman, Mark S, Selchen, Daniel, Prat, Alexandre, Giacomini, Paul S

“…Recent therapeutic advances in the management of multiple sclerosis (MS) have raised questions about the selection of appropriate patient candidates for…”
Get more information

Brain volume loss in individuals over time: Source of variance and limits of detectability by Narayanan, Sridar, Nakamura, Kunio, Fonov, Vladimir S., Maranzano, Josefina, Caramanos, Zografos, Giacomini, Paul S., Collins, D. Louis, Arnold, Douglas L.

“…Brain volume loss measured from magnetic resonance imaging (MRI) is a marker of neurodegeneration and predictor of disability progression in MS, and is…”
Get full text

Oculomotor analysis to assess brain health: preliminary findings from a longitudinal study of multiple sclerosis using novel tablet-based eye-tracking software by de Villers-Sidani, Étienne, Voss, Patrice, Bastien, Natacha, Cisneros-Franco, J. Miguel, Hussein, Shamiza, Mayo, Nancy E., Koch, Nils A., Drouin-Picaro, Alexandre, Blanchette, François, Guitton, Daniel, Giacomini, Paul S.

“…A growing body of evidence supports the link between eye movement anomalies and brain health. Indeed, the oculomotor system is composed of a diverse network of…”
Get full text

From progression to progress: The future of multiple sclerosis by Oh, Jiwon, Giacomini, Paul S, Yong, V Wee, Costello, Fiona, Blanchette, François, Freedman, Mark S

“…Significant advances have been made in the diagnosis and treatment of multiple sclerosis in recent years yet challenges remain. The current classification of…”
Get full text

The White Matter Rounds experience: The importance of a multidisciplinary network to accelerate the diagnostic process for adult patients with rare white matter disorders by Huang, Yu Tong, Giacomini, Paul S, Massie, Rami, Venkateswaran, Sunita, Trudelle, Anne-Marie, Fadda, Giulia, Sharifian-Dorche, Maryam, Boudjani, Hayet, Poliquin-Lasnier, Laurence, Airas, Laura, Saveriano, Alexander W, Ziller, Matthias Georg, Miller, Elka, Martinez-Rios, Claudia, Wilson, Nagwa, Davila, Jorge, Rush, Carolina, Longbrake, Erin E, Longoni, Giulia, Macaron, Gabrielle, Bernard, Geneviève, Tampieri, Donatella, Antel, Jack, Brais, Bernard, La Piana, Roberta

“…Adult genetic leukoencephalopathies are rare neurological disorders that present unique diagnostic challenges due to their clinical and radiological overlap…”
Get full text

Neurological complications of coronavirus infection; a comparative review and lessons learned during the COVID-19 pandemic by Sharifian-Dorche, Maryam, Huot, Philippe, Osherov, Michael, Wen, Dingke, Saveriano, Alexander, Giacomini, Paul S, Antel, Jack P, Mowla, Ashkan

“…Coronavirus disease-19 (COVID-19) pandemic continues to grow all over the world. Several studies have been performed, focusing on understanding the acute…”
Get full text

Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION-A 2-Year, Multicenter, Observational, Cohort Study by Butzkueven, Helmut, Giacomini, Paul S, Cohan, Stanley, Ziemssen, Tjalf, Sienkiewicz, Daniel, Zhang, Ying, Geissbühler, Yvonne, Silva, Diego, Tomic, Davorka, Kropshofer, Harald, Trojano, Maria

“…Multiple sclerosis (MS) patients receiving natalizumab and who are at risk of developing progressive multifocal leukoencephalopathy (PML) often switch to other…”
Get full text

Effects of fumarates on circulating and CNS myeloid cells in multiple sclerosis by Michell‐Robinson, Mackenzie A., Moore, Craig S., Healy, Luke M., Osso, Lindsay A., Zorko, Nika, Grouza, Vladimir, Touil, Hanane, Poliquin‐Lasnier, Laurence, Trudelle, Anne‐Marie, Giacomini, Paul S., Bar‐Or, Amit, Antel, Jack P.

“…Objective Dimethyl fumarate (DMF), a therapy for relapsing‐remitting multiple sclerosis (RRMS), is implicated as acting on inflammatory and antioxidant…”
Get full text

Rebound disease in multiple sclerosis by Giacomini, Paul S

Get full text

Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis by Li, Rui, Rezk, Ayman, Ghadiri, Mathab, Luessi, Felix, Zipp, Frauke, Li, Hulun, Giacomini, Paul S, Antel, Jack, Bar-Or, Amit

“…The therapeutic mode of action of dimethyl fumarate (DMF), approved for treating patients with relapsing-remitting multiple sclerosis, is not fully understood…”
Get full text

Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years by Hauser, Stephen L, Cross, Anne H, Winthrop, Kevin, Wiendl, Heinz, Nicholas, Jacqueline, Meuth, Sven G, Giacomini, Paul S, Saccà, Francesco, Mancione, Linda, Zielman, Ronald, Bagger, Morten, Das Gupta, Ayan, Häring, Dieter A, Jehl, Valentine, Kieseier, Bernd C, Pingili, Ratnakar, Stoneman, Dee, Su, Wendy, Willi, Roman, Kappos, Ludwig

“…Background: Ofatumumab is approved for the treatment of relapsing multiple sclerosis (RMS). Ongoing safety reporting is crucial to understand its long-term…”
Get full text

Pre-treatment T-cell subsets associate with fingolimod treatment responsiveness in multiple sclerosis by Ghadiri, Mahtab, Rezk, Ayman, Li, Rui, Evans, Ashley, Giacomini, Paul S., Barnett, Michael H., Antel, Jack, Bar-Or, Amit

“…Biomarkers predicting fingolimod (FTY) treatment response in relapsing-remitting multiple sclerosis (RRMS) are lacking. Here, we performed extensive functional…”
Get full text

Videoconferencing and Multiple Sclerosis Management: Stopgap or Stay Tuned? by Giacomini, Paul S, Oh, Jiwon, Morrow, Sarah A, Beauchemin, Philippe, Clift, Fraser, Devonshire, Virginia

Get more information

Dimethyl fumarate-induced lymphopenia in MS due to differential T-cell subset apoptosis by Ghadiri, Mahtab, Rezk, Ayman, Li, Rui, Evans, Ashley, Luessi, Felix, Zipp, Frauke, Giacomini, Paul S, Antel, Jack, Bar-Or, Amit

“…To examine the mechanism underlying the preferential CD8 vs CD4 T-cell lymphopenia induced by dimethyl fumarate (DMF) treatment of MS. Total lymphocyte counts…”
Get full text

Correction: Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis by Li, Rui, Rezk, Ayman, Ghadiri, Mahtab, Luessi, Felix, Zipp, Frauke, Li, Hulun, Giacomini, Paul S, Antel, Jack, Bar-Or, Amit

Get full text

Permanent tissue damage in multiple sclerosis lesions is associated with reduced pre-lesion myelin and axon volume fractions by Tagge, Ian J, Leppert, Ilana R, Fetco, Dumitru, Campbell, Jennifer SW, Rudko, David A, Brown, Robert A, Stikov, Nikola, Pike, G Bruce, Giacomini, Paul S, Arnold, Douglas L, Narayanan, Sridar

“…Background: The use of advanced magnetic resonance imaging (MRI) techniques in MS research has led to new insights in lesion evolution and disease outcomes. It…”
Get full text

Evaluation of automated techniques for the quantification of grey matter atrophy in patients with multiple sclerosis by Derakhshan, Mishkin, Caramanos, Zografos, Giacomini, Paul S., Narayanan, Sridar, Maranzano, Josefina, Francis, Simon J., Arnold, Douglas L., Collins, D. Louis

“…Several methods exist and are frequently used to quantify grey matter (GM) atrophy in multiple sclerosis (MS). Fundamental to all available techniques is the…”
Get full text

Quantitative magnetization transfer and myelin water imaging of the evolution of acute multiple sclerosis lesions by Levesque, Ives R., Giacomini, Paul S., Narayanan, Sridar, Ribeiro, Luciana T., Sled, John G., Arnold, Doug L., Pike, G. Bruce

“…Quantitative magnetization transfer imaging provides in vivo estimates of liquid and semisolid constituents of tissue, while estimates of the liquid…”
Get full text

Laquinimod in multiple sclerosis by Giacomini, Paul S, Bar-Or, Amit

“…Abstract Laquinimod is a novel, orally administered immune-modulatory molecule in advanced phase clinical trials in relapsing–remitting multiple sclerosis…”
Get full text